Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 6 Suggestion for the use of G-CSFs in individual cases. Usage of the GCSFs preparation for cervical cancer

From: A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

  Q19. CCRT for cervical cancera
  n = 114
I recommend G-CSFs on the following day of chemotherapy 6 (5.2)b
After Grade 4 neutropenia developed, I recommend G-CSFs 23 (20.2)
After FN developed, I recommend G-CSFs 26 (22.8)
I recommend G-CSFs to only high risk patients (Less than neutrophilic 100/mm3continues more than 10 days and/or fungal infectious disease) 35 (30.7)
I do not recommend G-CSFs 24 (21.1)
  1. CCRT Concurrent Chemoradiotherapy, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
  2. aA 30-year-old woman. We plan to concurrent chemoradiotherapy (cisplatin 40 mg/m2 on days 1, 8, 15, 22, 29, and 36) in patients with stage IIB cervical cancer (squamous cell carcinoma)
  3. bNumber (percent)